Back to Search
Start Over
Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians
- Source :
- Gut, 64(8), 1289-1295. BMJ Publishing Group
- Publication Year :
- 2015
-
Abstract
- Background Hepatocellular carcinoma (HCC) risk-scores may predict HCC in Asian entecavir (ETV)-treated patients. We aimed to study risk factors and performance of risk scores during ETV treatment in an ethnically diverse Western population. Methods We studied all HBV monoinfected patients treated with ETV from 11 European referral centres within the VIRGIL Network. Results A total of 744 patients were included; 42% Caucasian, 29% Asian, 19% other, 10% unknown. At baseline, 164 patients (22%) had cirrhosis. During a median follow-up of 167 (IQR 82-212) weeks, 14 patients developed HCC of whom nine (64%) had cirrhosis at baseline. The 5-year cumulative incidence rate of HCC was 2.1% for non-cirrhotic and 10.9% for cirrhotic patients (p
- Subjects :
- Adult
Male
Hepatitis B virus
medicine.medical_specialty
Carcinoma, Hepatocellular
Guanine
Population
medicine.disease_cause
Antiviral Agents
Risk Assessment
Gastroenterology
White People
Hepatitis B, Chronic
SDG 3 - Good Health and Well-being
Risk Factors
Internal medicine
medicine
Humans
Cumulative incidence
education
neoplasms
Retrospective Studies
education.field_of_study
business.industry
Incidence
Incidence (epidemiology)
Liver Neoplasms
Entecavir
Middle Aged
Hepatitis B
medicine.disease
United Kingdom
digestive system diseases
Surgery
Hepatocellular carcinoma
DNA, Viral
Female
business
Risk assessment
Follow-Up Studies
medicine.drug
Subjects
Details
- ISSN :
- 00175749
- Volume :
- 64
- Issue :
- 8
- Database :
- OpenAIRE
- Journal :
- Gut
- Accession number :
- edsair.doi.dedup.....85d16f88a8b7dd7dd1cf905724786331